Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of AG-348 in adults with pyruvate kinase deficiency
NL-OMON47068Phase 2Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mitapivat in pyruvate kinase deficiency (PKD) (3 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Safety and tolerability and Long-term safety and tolerability. Started Jan 2016; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NL-OMON47068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47068.